3:57 PM
Feb 20, 2018
 |  BC Extra  |  Company News

J&J execs launch Centyrins newco Aro

Two former Johnson & Johnson (NYSE:JNJ) executives have co-founded Aro Biotherapeutics Co. (Philadelphia, Pa.) to develop Centyrins for extra-hepatic, receptor-mediated delivery of oligonucleotides and other payloads. Aro President and CEO Susan Dillon was previously global therapeutic area head for immunology in the Janssen Pharmaceuticals unit...

Read the full 205 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >